Objective: The metabotropic glutamate receptor subtype 2 (mGlu 2 ) possesses both orthosteric and allosteric modulatory sites, are expressed in the frontal cortex and limbic structures, and can affect excitatory synaptic transmission. Therefore, mGlu 2 is a potential therapeutic target in the treatment of epilepsy. The present study seeks to evaluate the anticonvulsant potential of mGlu 2 -acting compounds. Methods: The anticonvulsant efficacy of two selective mGlu 2 -positive allosteric modulators (PAMs) (JNJ-42153605 and JNJ-40411813/ADX71149) and one mGlu 2/3 receptor agonist (LY404039) were evaluated alone and in combination with the antiseizure drug levetiracetam (LEV) in the mouse 6 Hz model. Results: In the 6 Hz (32 mA stimulus intensity) model, median effective dose (ED 50 ) values were determined for JNJ-42153605 (3.8 mg/kg), JNJ-40411813 (12.2 mg/kg), and LY404039 (10.9 mg/kg). At the 44 mA stimulus intensity, ED 50 values were determined for JNJ-42153605 (5.9 mg/kg), JNJ-40411813 (21.0 mg/kg), LY404039 (14.1 mg/kg), and LEV (345 mg/kg). In addition, subprotective doses of each mGlu 2 -acting compound, administered in combination with various doses of LEV, were able to shift the 6 Hz 44 mA ED 50 for LEV by >25-fold. When JNJ-42153605 was administered at varying doses in combination with a single dose of LEV (10 mg/kg), the potency of JNJ-42153605 was increased 3.7-fold. Similarly, when a moderately effective dose of LEV (350 mg/kg) was administered in combination with varying doses of JNJ-40411813, the potency of JNJ-40411813 was increased approximately 14-fold. Plasma levels of JNJ-40411813 and LEV were not different when administered alone or in combination, suggesting that increases in potency are not due to pharmacokinetic effects. Significance: These studies suggest a potential positive pharmacodynamic effect of mGlu 2 -acting compounds in combination with LEV. If this effect is translated in a clinical setting, it can support a rational polypharmacy concept in treatment of epilepsy patients.
Metabotropic glutamate receptors represent an attractive therapeutic target for various neurologic conditions. Within this family of receptors, the metabotropic glutamate receptor subtype 2 (mGlu 2 ) can affect excitatory synaptic transmission 1 and is therefore a potential therapeutic target in the treatment of epilepsy. This receptor possesses both orthosteric binding and allosteric modulatory sites, is expressed predominantly presynaptically, and is found in the frontal cortex and in limbic structures (e.g., hippocampus and amygdala). [2] [3] [4] Activation of mGlu 2 decreases glutamate release, likely through coupling to G-proteins (inhibitory/ other; G i/o ) and altering ion channel function or affecting neurotransmitter release, 1, 5, 6 and represents a potential new therapy for clinical states that involve excess glutamate activity. In human temporal lobe epilepsy, excess glutamate has been observed during both ictal and interictal periods. 7, 8 Following chemoconvulsant-induced status epilepticus, mGlu 2 receptor expression decreases, 9 likely due to neuronal loss, 10 and the subsequent loss of mGlu 2 -mediated reduction in glutamate release may contribute to hyperexcitability. Agonists of mGlu 2/3 have been shown to be effective in blocking or reducing seizures in pilocarpine-induced status epilepticus 11, 12 and in the 6 Hz model. 13 Because the initial discovery of positive allosteric modulators (PAMs) of mGlu 2 , 14, 15 there has been great interest in the potential of these compounds for clinical use. A PAM binds to a receptor site that is different from glutamate and offers an alternative approach for enhancing mGlu 2 activity. Furthermore, mGlu 2 PAMs have minimal effects when administered alone yet can modulate the overall response to glutamate. Because these compounds do not activate the receptor directly, they may avoid tachyphylaxis, further adding to their therapeutic potential. Recently mGlu 2 PAMs have been examined as potential therapies for schizophrenia and psychosis, [16] [17] [18] and they also represent a novel therapeutic target for the treatment of epilepsy.
Agonists of mGlu 2/3 can reduce (but not eliminate) pilocarpine-induced seizures, 19 block 6 Hz (32 mA) induced seizures, 13 reduce audiogenic seizures in Dilute Brown Non-Agouti (DBA/2) mice, 20 reduce pentylenetetrazoleinduced seizures, 20 and reduce seizure behaviors in amygdalakindled rats. 20 Although PAMs for other metabotropic glutamate receptors have been evaluated in several seizure models, 21, 22 there is little information available describing the effect of mGlu 2 or mGlu 3 PAMs in models of seizures and epilepsy.
The synaptic vesicle protein 2A (SV2A) is a target for antiseizure therapy with clinical utility in both partial and generalized seizures. SV2A plays a key role in neurotransmission 23 and affects glutamatergic and c-aminobutyric acid (GABA)ergic neurotransmitter systems. 24, 25 Ligands for SV2A such as levetiracetam (LEV) and brivaracetam have proven effective in the treatment of epilepsy, although clinical use of LEV can be hindered by dose-limiting side effects. For example, LEV can produce aggression, nervousness/anxiety, somnolence, and fatigue. 26, 27 Despite noted side effects, LEV can be used as a monotherapy or as adjunctive treatment for a variety of seizure indications. 27 It is not known whether combination with other antiseizure drugs can reduce the doses of LEV needed to achieve therapeutic efficacy. 28 The 6 Hz model of psychomotor seizures is one of the validated epilepsy animal models that has been used for preclinical evaluation of several antiseizure drugs. 29 Furthermore, testing using both the 32 and 44 mA stimulus intensities can be used to differentiate compounds with potential utility for treatment-refractory epilepsy. Herein we describe the determination of anticonvulsant efficacy of two selective mGlu 2 PAMs-JNJ-40411813 (ADX71149) 30 and the more potent JNJ-42153605 31 -in comparison to the mGlu 2/3 agonist LY404039 32, 33 in the 6 Hz seizure model using both 32 and 44 mA stimulus intensities.
In clinical practice, antiseizure drugs are often used in combination with control seizures in patients with epilepsy. LEV is recognized as an effective antiseizure drug and is often used in combination therapy. The preclinical profile of LEV differentiates itself from other antiseizure drugs in its lack of activity in maximal electroshock and chemoconvulsant seizure models despite significant clinical efficacy. Because antiseizure drugs are often used in combination, we investigated whether a combination of LEV and the mGlu 2 2/3 agonists enhance the efficacy and potency of one of the current gold standard treatments (LEV) in a widely employed preclinical model of therapy-resistant seizures, and may inform the design and execution of future clinical trials rodents. 18, 31, 34 JNJ-40411813, JNJ-42153605, and LY404039 have been examined previously for potential antipsychotic activity. 18, 35 Therefore, the studies described herein further extend the preclinical profile and potential clinical utility of mGlu 2 -acting compounds. Moreover, they describe a powerful synergistic effect when they are used in combination with LEV.
Methods

Compound preparation
A 40% hydroxypropyl-beta-cyclodextrin (HPbCD; Sigma, St. Louis, MO, U.S.A.) preparation was used for preparation of stock solutions of JNJ-42153605 and JNJ-40411813. The compounds were stirred on a heated plate (~70°C) until dissolution, and the pH was adjusted to 4. Sterile water was added to the final solution so that the final concentration of the dosing solution also contained 20% HPbCD. Typically, dosing solutions were prepared fresh on the day of testing. Occasionally, dosing solutions from a previous preparation within a study were used (no more than 3 days old, stored at 4°C, and warmed to room temperature prior to dosing). All dosing solutions were mixed thoroughly prior to administration. The vehicle (VEH) solution for JNJ-42153605 and JNJ-40411813 was 20% HPbCD. LY404039 was initially prepared in sterile water with a small amount of 0.1 N sodium hydroxide. The compound was stirred on a heated plate (~70°C) until dissolution. Sterile water was added (10% of final volume) and the pH adjusted to~8.5. Sodium chloride was added to the final stock solution (0.9% NaCl). The VEH solution for LY404039 was 0.9% NaCl. LEV was prepared in a 0.5% methylcellulose (Sigma) solution. The VEH for LEV (Sigma) was 0.5% methylcellulose.
Animals and compound administration
Adult male Carworth Farms (CF-1) mice (25-40 g ), used for the 6 Hz and corneal kindling assays, were obtained from Charles River (Portage, MI, U.S.A.). Animals were allowed free access to food and water, except during testing periods. After delivery, animals were allowed sufficient time to acclimate to housing conditions prior to testing. All mice were housed in plastic cages in rooms with controlled humidity, ventilation, and lighting (12 h on/12 h off). The animals were housed and fed in a manner consistent with the recommendations in the "Guide for Care and Use of Laboratory Animals" (National Research Council), and in accordance with guidelines set by the Institutional Animal Care and Use Committee of the University of Utah. Animal experiments were conducted in a manner consistent with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (https://www.nc3rs.org.uk/arriveguidelines). Test compounds were administered using an optimal fluid volume-to-body fluid ratio. Test compounds were administered to mice in a volume of 0.01 ml/g body weight. JNJ-42153605, JNJ-40411813, and LY404039 were administered by subcutaneous (s.c.) injection and LEV was administered by intraperitoneal (i.p.) injection.
Hz psychomotor seizure test
Focal seizures were induced in mice via corneal stimulation (6 Hz, 0.2 msec rectangular pulse, 3 s duration 29 ). Mice were tested at either 32 mA or 44 mA stimulus intensities. Prior to stimulation, drops of 0.5% tetracaine were applied to each eye. The seizures that arise from corneal stimulation in this assay are characterized by a minimal clonic phase followed by stereotyped automatistic behaviors including stun, forelimb clonus, twitching of the vibrissae, and Straub-tail. If any of these behaviors occurred during a 1 min observation period following stimulation, the animal was considered as having demonstrated a seizure. Animals not displaying any of the behaviors noted above were considered "protected." Separate studies were conducted to evaluate dose-response relationships for each compound using either 32 mA or 44 mA stimulus intensities. Initial time-course studies were conducted to determine pretreatment times for each compounds. Pretreatment times were 0.25 h (JNJ-42153605), 0.5 h (JNJ-40411813, and LY404039), and 1 h (LEV). A median effective dose (ED 50 ) and 95% confidence interval (CI) were calculated using a Probit analysis. For combination studies, compounds were administered using the same pretreatment time and route used for single administration studies.
Rotarod test for motor impairment
Testing in the rotarod was conducted in tandem with 6 Hz stimulation to verify whether doses administered produced substantial motor impairment. Evaluation in the rotarod assay was conducted immediately prior to 6 Hz testing. Therefore, each treatment group was subjected to evaluation in the rotarod assay followed immediately by testing in the 6 Hz assay. When mice are placed on a 1-inch knurled rod rotating at a speed of 6 rpm, the animals can maintain equilibrium for long periods. Motor impairment was assessed by determining whether mice remained on the rotarod during a 1 min observation period; that is, three falls during a 1 min period was considered a rotarod failure.
Serum collection for analysis of plasma drug levels
In various tests, animals were sacrificed following testing, and trunk blood was collected for quantification of drug levels. Immediately after testing, animals were decapitated and trunk blood was collected into a BD Vacutainer tube containing dipotassium ethylenediaminetetraacetic acid (K2EDTA) and chilled on ice until centrifugation. Following centrifugation (10,000 g, 5-7 min), the plasma was removed and transferred to a labeled microcentrifuge tube and stored at À80°C until shipment to the sponsor. The frozen sample was placed in a labeled centrifuge tube and stored at À80°C until analysis of samples. Compound levels were detected using liquid chromatography/tandem mass spectrometry (API-4000 LC/MS/MS system; Applied Biosystems, Cheshire, United Kingdom).
Statistical analysis
Seizure protection and rotarod motor impairment data are presented as # protected/N tested and # with motor impairment/N tested, respectively. A Fisher exact test was used to compare motor impairment values for specific treatment groups with VEH-treated animals. For dose-response analyses, ED 50 (and 95% CI) values were calculated using a Probit analysis wherein at least four treatment groups (N = 8 per group) were used in the calculation. Plasma levels are presented as means AE standard error and were compared using a Student's t-test.
Results
Anticonvulsant screening in the 6 Hz model
In the 6 Hz model, the selective mGlu 2 PAM JNJ-42153605 was potently active in the 6 Hz seizure model, at both 32 mA (Fig. 1A ) and 44 mA (Fig. 1B) stimulus intensities. ED 50 (95% CI) values were 3.8 mg/kg (1.6-6.7) and 5.9 mg/kg (3.9-8.5), for 32 and 44 mA, respectively (see Table 1 ). In the 32 mA test, no rotarod failures were observed at any of the doses tested, whereas, in the 44 mA assay, a dose of 40 mg/kg produced moderate motor impairment (# rotarod failures/# tested: 2/8), which did not differ significantly from that in VEH-treated mice (# rotarod failures/# tested: 0/8). No rotarod failures were observed at any other dose tested. Receptor occupancy studies in naive animals suggest that the doses tested in the 6 Hz model should provide full receptor occupancy (data not shown).
A second selective mGlu 2 PAM, JNJ-40411813, was active in the 6 Hz seizure model, at both 32 mA (Fig. 1A ) and 44 mA (Fig. 1B) Table 1 ). There were no significant differences in motor impairment for any treatment group (doses up to 40 mg/kg) compared to VEH. In the 32 mA test, 2.5/5/10 mg/kg doses produced minimal motor impairment (1/8, 0/8, 0/8 rotarod failures, respectively; not significantly different from VEH-treated controls), whereas doses of 20 and 40 mg/kg produced three of eight and two of eight rotarod failures, respectively, which The mGlu 2/3 agonist LY404039 was active in the 6 Hz seizure model, at both 32 mA (Fig. 1A ) and 44 mA (Fig. 1B) stimulus intensities. ED 50 (95% CI) values were 10.9 mg/kg (7.8-15.9) and 14.1 mg/kg (10.0-20.6) for 32 and 44 mA, respectively (see Table 1 ). In the 32 mA assay, motor impairment did not exceed 13% at doses up to 40 mg/kg (1/16, 0/8, 1/8, and 1/8 rotarod failures for 5, 10, 20, and 40 mg/kg, respectively). In the 44 mA assay, motor impairment did not exceed 13% at doses up to 20 mg/kg (0/ 16, 1/8, and 1/8 rotarod failures for 5, 10, and 20 mg/kg, respectively), and 25% motor impairment (2/8 rotarod failures; not significantly different vs. VEH) was observed at a dose of 40 mg/kg.
LEV has been previously evaluated in 6 Hz model 29 ; in particular, LEV shows a substantial shift in potency between 32 and 44 mA stimulus intensities. For the purposes of this study, we evaluated LEV in the 6 Hz (44 mA) assay following intraperitoneal administration (see Fig. 1B ). LEV was tested at different doses with dosedependent efficacy observed and an ED 50 (95% CI) of 345.4 mg/kg (211.0-485.3; see Table 1 ). No motor impairment was observed following any dose of LEV tested.
Of the compounds evaluated, JNJ-42153605 was the most potent in the 6 Hz assay. JNJ-42153605, JNJ-40411813, and LY404039 all show a minimal shift in potency between 6 Hz stimulus intensities (1.3-1.7-fold shift in potency), whereas LEV was much less potent (18-fold shift in potency between the previously described 32 mA ED 50 and the 44 mA ED 50 determined in this study).
Combination of mGlu 2 -acting compounds with LEV in the 6 Hz (44 mA) test
Following dose-response studies for each of the three test compounds in the 6 Hz assay, we next sought to evaluate each compound in combination with LEV in the 6 Hz (44 mA) assay. A minimally effective dose (3 mg/kg administered alone produced 1/8 mice protected) of JNJ-42153605 was used in combination with various doses of LEV (Fig. 2) . When used alone, full protection was not attainable with LEV alone in the 6 Hz (44 mA) test. In contrast, when JNJ-42153605 (3 mg/kg) was used in combination with LEV at doses of 100 and 10 mg/kg, full protection was observed. The ED 50 (95% CI) for LEV combination with JNJ-42153605 was 1.0 mg/kg (0.2-2.3), which is >400-fold more potent than when LEV was administered alone in this assay (Table 3) .
A subprotective dose of JNJ-40411813 (10 mg/kg, this dose was ineffective in the 6 Hz 44 mA assay when administered alone, 0/16 protected) was used in combination with various doses of LEV (see Fig. 2) . A high level of efficacy (>75% protection) was observed at doses over 25 mg/kg LEV. The ED 50 (95% CI) for LEV combination with JNJ-40411813 was 9.6 mg/kg (1.7-21.9), which is >35-fold more potent than when LEV was administered alone in this assay (see Table 3 ).
A subprotective dose of LY404039 (5 mg/kg; this dose alone was ineffective, 0/16 protected) was used in combination with various doses of LEV. A high level of efficacy (>75% protection) was observed when used in combination with 20 mg/kg or higher doses of LEV (see Fig. 2 ). The ED 50 (95% CI) for LEV combination with LY-4040439 was 12.8 mg/kg (2.5-25.2), which is >26-fold more potent than when LEV was administered alone in this assay (see Table 3 ).
To further explore the possible effects of JNJ-40411813 in combination with LEV, a moderately effective dose (350 mg/kg, similar to 6 Hz 44 mA ED 50 value for LEV) was combined with various doses of JNJ-40411813. When administered alone, the ED 50 value for JNJ-40411813 was 21 mg/kg (see Table 1 ). When combined with LEV (350 mg/kg), JNJ-40411813 was~14-fold more potent (ED 50 , 95% CI for JNJ-40411813 when combined with LEV 350 mg/kg: 1.3 mg/kg, 0.3-2.2; see Table 2 ).
In addition to the subprotective doses of each test compound in the presence of various doses of LEV, we sought to determine whether an inactive dose of LEV would lead to a shift in potency of JNJ-42153605 (see Fig. 3 ). LEV was administered at a dose of 10 mg/kg (well below a minimally effective dose of 200 mg/kg, 25% efficacy, 2/8 protected, see Fig. 1B ) in combination with JNJ-42153605 at various doses. The ED 50 (95% CI) for JNJ-42153605 in combination with LEV was 1.6 mg/kg (0.9-2.7), more than threefold more potent than JNJ-42153605 administered alone (see Table 3 ).
Analysis of plasma levels of selected compounds
To further evaluate the effect of JNJ-40411813 in combination with LEV, trunk blood samples were collected immediately following testing in the 6 Hz (44 mA) model. JNJ-40411813, 10 mg/kg, plasma levels were not significantly different when administered in combination with LEV, 350 mg/kg, or when administered alone (Table S1) . Similarly, plasma levels of LEV, 350 mg/kg, were not significantly different when administered alone or administered in combination with JNJ-40411813, 10 mg/kg (Table S1 ).
Discussion
The present investigation further defines the antiseizure potential of mGlu 2 PAMs in a model of therapyresistant seizures alone and in combination with LEV.
Each of the two mGlu 2 PAMs evaluated in this study were potently effective in the 6 Hz assay at both 32 and 44 mA stimulus intensities. In addition, activity observed by the mGlu 2/3 receptor agonist, LY404039, suggests that both orthosteric and allosteric receptor activation confers efficacy in the mouse 6 Hz model. Many clinically available antiseizure drugs effective in the 32 mA stimulus intensity lose potency or are ineffective at the higher stimulus intensity, 29 and therefore testing using the 44 mA stimulus intensity is considered a model of pharmacoresistant epilepsy. Furthermore, whereas LEV loses potency and efficacy in the 44 mA test, efficacy is reestablished when LEV is coadministered with a subprotective dose of JNJ-42153605, JNJ-40411813, or LY404039. This observation adds to the potential clinical utility of mGlu 2 -acting compounds as add-on therapeutic agents, an observation that may inform future clinical trial design with this new class of neuromodulatory compounds.
Excess glutamate can be a key factor contributing to the pathophysiology of epilepsy. Therefore, modulation of glutamate transmission is critical in controlling seizures. Presynaptic mGlu 2/3 can play a role in blocking seizures through a reduction in excess glutamate levels by modulating synaptic release. 20, 36 Moreover, in a model of pilocarpineinduced SE, mGlu 2/3 agonists affected the onset and maintenance of SE, 11 consistent with the hypothesis that mGlu 2 can reduce glutamate release and thereby progression of SE. Furthermore, these receptors are located perisynaptically 37, 38 (in addition to presynaptic localization) and are therefore likely to be activated under conditions of excess Table 3 ). N = 8-16 per group. Epilepsia ILAE LEV was administered by intraperitoneal injection 1 h prior to testing in the 6 Hz and motor impairment (rotarod) assays. JNJ-40411813 was administered by subcutaneous injection 0.5 h prior to testing.
glutamate, which may spill over to regions outside of the synapse.
In these studies, plasma levels of JNJ-40411813 and LEV do not differ whether they are administered alone or in combination. The levels of JNJ-40411813 observed at a dose of 10 mg/kg are similar to the EC 50 value (~1,200 ng/ml), obtained from pharmacokinetic-pharmacodynamic modeling based on receptor occupancy studies in rats. 39 Similarity in plasma levels for each of JNJ-40411813 administered alone or in combination suggests that there are not likely pharmacokinetic effects (i.e., inhibition of metabolism) that contribute to the superior efficacy observed with coadministration of the two compounds. However, the mechanism underlying this potentiation is not currently known and warrants further investigation.
Treatment with JNJ-40411813 at doses of 20 or 40 mg/ kg produced notable motor impairment in the rotarod assay, suggesting an approximate median dose of 40 mg/kg for motor impairment and a therapeutic index (median dose for motor impairment/ED 50 ) of 1-3. By contrast, LY404039 and JNJ-42153605 did not produce >25% motor impairment at the highest doses tested. It is noteworthy that the combined administration of subprotective doses of mGlu 2 -acting compounds with LEV conferred protection in the 6 Hz (44 mA) assay, whereas LEV alone requires substantially higher doses for seizure protection. Furthermore, LEV is known to be well tolerated in mice (median toxic dose following i.p. administration >500 mg/kg) 29, 40 but is not active in some animal models including maximal electroshock, subcutaneous pentylenetetrazol, and 6 Hz (44 mA). 29, 40 Therefore, the combination of subprotective doses of mGlu 2 -acting compounds with LEV protected against seizures at doses that did not produce motor impairment or other signs of behavioral side effects.
LEV has been studied previously in combination with other antiseizure drugs and with novel compounds. In the mouse maximal electroshock model, retigabine and LEV were synergistically effective in blocking seizures for some fixed dose-ratio combinations using isobolographic analysis. 41 Similarly, using isobolographic evaluation in the mouse 6 Hz model, LEV in combination with carbamazepine, lacosamide, phenytoin, topiramate, phenobarbital, and vigabatrin demonstrated synergistic activity, albeit not for all dose-ratio combinations. [42] [43] [44] Furthermore, the novel synthetic cannabinoid WIN 55,212-2 enhanced the effect of LEV in the mouse 6 Hz model, 45 whereas other novel compounds for epilepsy have not demonstrated positive pharmacodynamic interactions with LEV. 46, 47 Therefore, both established and potential antiseizure drugs have been evaluated in combination with LEV, and potentially beneficial combinations can be used to inform both current clinical therapy and clinical trial design for novel compounds. In these studies, mGlu 2 PAMs demonstrate potentially beneficial positive pharmacodynamic interactions with LEV. However, it is noteworthy that more definitive preclinical studies (e.g., isobolographic analysis) will be important before the clinical benefits of such a combination are evaluated in patients with epilepsy. Current therapy to control seizures in persons with epilepsy often includes two or more concomitant medications. 48 Although for some individuals this therapeutic regimen can reduce or prevent seizures, 49 LEV add-on therapy has been associated with dose-limiting side effects in some patients, 50 but not in others. 49 Common side effects of LEV (1,000-3,000 mg/day) include somnolence, asthenia, and headache. 49, 51 Furthermore, LEV has been associated with negative psychological effects such as irritability, aggression, and suicidal ideation. [52] [53] [54] An effective combination of LEV with other drug(s) that retains efficacy while diminishing treatment-emergent side effects would be important, as it would provide protection against seizures while decreasing total body exposure to a drug that is often administered chronically. In clinical trials, adjunctive LEV therapy has been shown to improve seizure control in patients with drug-refractory epilepsy, reduce the incidence of psychiatric side effects, and improve quality of life. 54 In the current study, combinations of mGlu 2 -acting compounds and LEV at doses that were highly efficacious also did not produce motor impairment or other observable signs, suggesting good tolerability of the combination. Because it is difficult to study the potential for psychiatric side effects following LEV administration in a preclinical model, the lack of motor impairment or behavioral side effects suggests that combined treatment of mGlu 2 -acting agents with LEV is well tolerated.
In addition, a combined therapeutic approach should also be devoid of drug-drug interactions that can limit clinical utility. In order to verify whether a combined therapy would be beneficial, plasma levels should be consistent whether each compound is administered alone or in combination. LEV has not been associated previously with pharmacokinetic interactions when coadministered with other antiseizure drugs. 49 When JNJ-40411813 was administered in combination with LEV, the plasma levels were consistent regardless of whether the compounds were administered alone or in combination. This suggests a low potential for drug-drug interactions and a likelihood that efficacy observed in combination represents a positive pharmacodynamic effect.
In conclusion, mGlu 2 -acting compounds described herein, including two mGlu 2 PAM compounds and one mGlu 2/3 agonist, were highly effective in the 6 Hz model of psychomotor seizures, including efficacy at the higher (44 mA) stimulus intensity. To further demonstrate potential clinical utility of mGlu 2 -acting compounds, each compound was combined with the SV2A-acting antiseizure drug LEV in the 6 Hz (44 mA) model and demonstrated superior efficacy in comparison to LEV administered alone. Plasma levels rule out any pharmacokinetic interaction. The mechanism underlying the positive interaction between LEV and mGlu 2 -acting compounds is not currently known and deserves further investigation. It is noteworthy that mGlu 2 receptors are activated under conditions of high synaptic activity, as occurs during seizures, wherein excess glutamate may spill over perisynaptically. 55 Furthermore, because mGlu 2 receptors are also located presynaptically, 4, 37, 38, 56 activation of these receptors during seizures may reduce the probability of neurotransmitter release. Given that SV2A plays a role in neurotransmitter release, the combined action of LEV on SV2A and agonists or modulators of mGlu 2 may substantially diminish neurotransmitter release probability. Further evaluation of the potential interactions between mGlu 2 -acting compounds and LEV should include a more definitive combination study utilizing isobolographic analysis with tissue sampling (plasma and brain) to confirm pharmacodynamic rather than pharmacokinetic mechanisms underlying this interaction. In addition, further studies are needed to determine the mechanism underlying the interaction between concomitant action at SV2A and mGlu 2 sites that confers a high potency in preclinical seizure models. Furthermore, future work may include evaluation of potential combined effects of mGlu2-acting compounds such as JNJ-40411813 in combination with SV2A-acting compounds such as brivaracetam. Similarly, additional studies can investigate whether the observed synergy between mGlu 2 -acting compounds and LEV is specific or whether mGlu 2 -acting compounds can exert a similar synergistic effect with antiseizure drugs with a different mechanism of action as SV2A. If there is an observed synergistic effect unique to the interaction of mGlu 2 and SV2A, our work provides support for a rational polypharmacy concept in the treatment of epilepsy, a concept that might transform the treatment of patients with epilepsy.
